IDH1/IDH2 Inhibition in Acute Myeloid Leukemia

Recently, the discovery of biological and clinical properties of mutated isoforms 1 and 2 mutations of isocitrate dehydrogenases (IDH) 1 and 2, affecting approximately 20% of patients with acute myeloid leukemia (AML), lead to the development of an individualized treatment strategy. Promoting differ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Cerchione, Claudio, Romano, Alessandra, Daver, Naval, DiNardo, Courtney, Jabbour, Elias Joseph, Konopleva, Marina, Ravandi-Kashani, Farhad, Kadia, Tapan, Martelli, Maria Paola, Isidori, Alessandro, Martinelli, Giovanni, Kantarjian, Hagop
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8063727/
https://ncbi.nlm.nih.gov/pubmed/33898313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.639387
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados